HIV-1 Superinfection in the Antiretroviral Therapy Era: Are Seroconcordant Sexual Partners at Risk? by Campbell, Mary S. et al.
HIV-1 Superinfection in the Antiretroviral Therapy Era:
Are Seroconcordant Sexual Partners at Risk?
Mary S. Campbell
1*, Geoffrey S. Gottlieb
1, Stephen E. Hawes
3, David C. Nickle
4, Kim G. Wong
2, Wenjie
Deng
2, Thomas M. Lampinen
6, Nancy B. Kiviat
5, James I. Mullins
1,2
1Department of Medicine, School of Medicine, University of Washington, Seattle, Washington, United States of America, 2Department of Microbiology, University of
Washington, Seattle, Washington, United States of America, 3Department of Epidemiology, School of Public Health & Community Medicine, University of Washington,
Seattle, Washington, United States of America, 4Rosetta InPharmatics/Merck & Co., Seattle, Washington, United States of America, 5Department of Pathology, School of
Medicine, University of Washington, Seattle, Washington, United States of America, 6School of Population and Public Health, University of British Columbia, Vancouver,
Canada
Abstract
Background: Acquisition of more than one strain of human immunodeficiency virus type 1 (HIV-1) has been reported to
occur both during and after primary infection, but the risks and repercussions of dual and superinfection are incompletely
understood. In this study, we evaluated a longitudinal cohort of chronically HIV-infected men who were sexual partners to
determine if individuals acquired their partners’ viral strains.
Methodology: Our cohort of HIV-positive men consisted of 8 couples that identified themselves as long-term sexual
partners. Viral sequences were isolated from each subject and analyzed using phylogenetic methods. In addition, strain-
specific PCR allowed us to search for partners’ viruses present at low levels. Finally, we used computational algorithms to
evaluate for recombination between partners’ viral strains.
Principal Findings/Conclusions: All couples had at least one factor associated with increased risk for acquisition of new HIV
strains during the study, including detectable plasma viral load, sexually transmitted infections, and unprotected sex. One
subject was dually HIV-1 infected, but neither strain corresponded to that of his partner. Three couples’ sequences formed
monophyletic clusters at the entry visit, with phylogenetic analysis suggesting that one member of the couple had acquired
an HIV strain from his identified partner or that both had acquired it from the same source outside their partnership. The 5
remaining couples initially displayed no evidence of dual infection, using phylogenetic analysis and strain-specific PCR.
However, in 1 of these couples, further analysis revealed recombinant viral strains with segments of viral genomes in one
subject that may have derived from the enrolled partner. Thus, chronically HIV-1 infected individuals may become
superinfected with additional HIV strains from their seroconcordant sexual partners. In some cases, HIV-1 superinfection
may become apparent when recombinant viral strains are detected.
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Introduction
Data from case reports and cohort studies have established that
infection with more than one strain of human immunodeficiency
virus type 1 (HIV-1)– termed dual infection– does occur. Dual
infection encompasses both co-infection, acquisition of two
separate viral strains during primary infection, and superinfec-
tion, acquisition of one or more viral strains after seroconversion.
The phenomena of HIV-1 dual and superinfection have been
reported in a variety of risk groups, including men who have sex
with men (MSM), heterosexual women, infants, and injection
drug users (IDU) [1–23], and are relevant to HIV clinical care,
epidemiology, and the design of prevention strategies. Superin-
fection may lead to acquisition of drug-resistant strains [24,25]
and has been associated with accelerated disease progression
[10,26]. The presence of multiple viral strains within a host
permits inter- and intra-subtype recombination, which increases
global HIV diversification [5,21,22,27–29]. Finally, research on
dual and superinfection is pertinent to the development of
preventive approaches, as it is clear that in some instances HIV-
positive individuals are vulnerable to repeated infection with
other viral strains.
A subgroup for which limited data on dual infection exists is that
of HIV-1 seroconcordant partners. Few such cohorts are available
for evaluation, yet insight into the risks of sexual transmission in
seroconcordant couples is highly desirable for the purposes of
individual and public health. Studying sexual partners also allows
for greater scrutiny for evidence of viral transmission than in other
individuals, using both molecular and computational techniques.
With this rationale, we undertook the following examination for
dual and superinfection in our cohort of HIV-1 seroconcordant
long-term sexual partners who were MSM.
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Participants
Sixteen HIV-1-infected MSM who identified themselves as
long-term sexual partners in the Male Anal Health Study (MAHS)
were included in this analysis. The MAHS is a longitudinal cohort
designed to examine the role of HIV-1 in the development of anal
dysplasia [30], composed of 337 men, recruited in Seattle,
Washington between 1996–2000. Volunteers gave written in-
formed consent for participation. The study was approved by the
University of Washington Human Subjects Review Committee
and was conducted in accordance with the principles of the
Helsinki Declaration. Participants returned at 4-month intervals
and completed questionnaires regarding demographics, behavior,
and health and underwent physical examinations and collection of
blood and anorectal swabs. In this paper, participants were
designated with identification numbers different from those used
during study follow-up to protect the confidentiality of the
volunteers.
Specimen collection and clinical testing
At each visit, serum, whole blood, and anorectal swabs were
obtained for HIV-1 quantification, as described [30]. Specimens
available for this study included DNA from peripheral blood
mononuclear cells (PBMC) and anorectal swabs.
HIV-virus isolation, PCR, cloning, and sequencing
We examined HIV-1 sequences from PBMC from the initial
and final study visits. In some individuals, we were also able to
obtain HIV-1 sequences from cell pellets from anorectal swab
specimens. Our methods for DNA extraction, PCR, cloning, and
sequencing are described in detail in previous publications [31–
34]. Briefly, we used endpoint serially diluted genomic DNA
extracted from PBMC or anorectal swabs to perform nested PCR
to amplify the ,637 nucleotide-long C2-V5 fragment of the HIV-
1 envelope gene (env). PCR products were cloned in plasmids and
sequenced with the dideoxy terminator technique. To minimize
risk of sample mix-up and contamination, we avoided working
with specimens from a given subject and his partner simulta-
neously. Sequences were submitted to GenBank (accession
numbers FJ975207–FJ975545).
Phylogenetic analysis
We screened for specimen mix-up and contamination using the
Los Alamos National Laboratory (LANL) HIV sequence database
(http://hiv-web.lanl.gov) [35] and our internal sequence database
(http://indra.mullins.microbiol.washington.edu/blast/viroblast.
php). Alignments were created with CLUSTALW [36] and
manually adjusted in MacClade v4.08 [37]. PAUP* v4.0b10 [38]
was used to generate distance matrices and neighbor-joining (NJ)
and maximum-likelihood (ML) phylogenies.
Strain-specific PCR
For couples whose HIV-1 sequences were phylogenetically
distinct, we sought to identify low-level superinfection using
specific primers to amplify a subject’s viral variants within his
partner’s PBMC-derived HIV DNA, the only blood-derived
specimens available for this study. We designed primers using
nucleotide alignments that flanked unique sequence regions in
each subject’s env gene. Our goal was to target regions of env that
were conserved in an individual participant, but distinct from that
in the partner and thus could best distinguish viruses in the couple.
Nested PCR was performed, using primers DR7 and DR8 [31] in
the first round, which amplifies the 637 nucleotide C2-V5 region
of envelope, and specific primers for the second round. Gel
electrophoresis was used to ascertain whether fragments of
appropriate length had been amplified. We first tested DNA from
env clones from each subject and his partner to determine the
sensitivity and specificity of the primers, with a limit of detection of
1–2 copies per PCR reaction. After it was found that the primers
both amplified the region of interest from a subject’s viral clone
and failed to generate non-specific bands from that of his partner,
PCR was performed using PBMC-derived DNA.
Recombination analysis
To further investigate for superinfection, we searched for viral
recombination in pairs whose viruses were phylogenetically
distinct (pairs A, B, E, F, and I) using two methods. We first
used the Recombinant Identification Program (RIP version 3.0,
http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html). The
algorithm uses a sliding window method to determine if a query
sequence from an individual matches sequences in a background
alignment of viral sequences derived from that individual and his
partner. We performed this analysis for pairs A, B, E, F, and I,
using a window size of 100 and significance threshold of 90%.
Since the various recombination detection methods that are
available may yield different results, we also evaluated the data
with the InSites algorithm (http://indra.mullins.microbiol.
washington.edu/cgi-bin/InSites/index.cgi), which has been used
to detect recombinant sequences by visual inspection of shared
nucleotide sites in an alignment [39]. We used CLUSTALW and
MacClade v4.08 to create separate nucleotide alignments for each
pair, which in turn allowed us to derive a consensus sequence for
the pair. Using the consensus sequence as the reference sequence,
we used the alignment as input for the InSites program, which
generates an output of phylogenetically informative sites, i.e. sites
in the alignment with nucleotides that differ from the reference
sequence, but are shared by two or more non-reference sequences,
as described in Gottlieb et al. [39]. This permitted visualization of
sites with nucleotides that were present in a large portion of one
subject’s sequences that were also shared by a subset of another
subject’s sequences. We performed this analysis with sequences
from enrolled couples, as well as with sequences from pairs of
subjects in the cohort that had no known epidemiologic linkage.
Results
Demographic and clinical data
We evaluated HIV-1 sequences in 8 pairs of MSM at two visits
11–71 months apart (median 55.3 months). At study entry, their
CDC-defined HIV disease classification ranged from A1-C3. Five
had baseline CD4
+ counts #200 cells/ul and eleven had
detectable plasma viral loads (Table 1).
These couples reported sexual partnerships of 3 to 15 years
duration prior to enrollment in the MAHS. In some cases, the
subjects’ perception of the timing of their HIV acquisition pre-
dated partnership formation, but others reported a perceived time
of HIV infection and laboratory confirmation which corresponded
with partnership formation (Table 1).
All but one subject underwent treatment with ART while
enrolled. However, only 4 had sustained virological suppression at
all visits (Table 1). On a per-couple basis, it was evident that all
couples had periods during which at least one partner had a
detectable viral load, ranging from 10–100% of visits.
Although no infections with gonorrhea, chlamydia, or syphilis
were reported during the study, all participants had anogenital
HPV lesions and participants from 5 couples (6 individuals)
reported anogenital herpes simplex virus (HSV) recurrences
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PLoS ONE | www.plosone.org 3 May 2009 | Volume 4 | Issue 5 | e5690(Table 2). None of the subjects developed AIDS-defining
conditions or CD4
+ counts #200 cells/ul during the study.
Behavioral data
Surveys of self-reported sexual behavior were available for all
but one participant at study entry and during follow-up (Table 3).
At baseline, 9 subjects reported having casual male partners in
addition to their primary partner within the past year, with a
median of 1.5 partners, range 1–50 (Table 3). There were a
median of 4.5 (range 0–40) and 6 (range 0–40) episodes of insertive
and receptive anal intercourse respectively during the 4 months
prior to study entry, ,77% of which took place without condoms.
During the follow-up period, representing ,68 person-years of
observation, only 3 subjects reported monogamous relationships
with their enrolled partners. The median number of additional
sexual partners was 10.5 (range 0–24). Participants reported 2091
episodes of anal intercourse during the follow-up period, ,73% of
which were unprotected. On a per-couple basis, the proportion of
episodes of unprotected anal intercourse ranged from 0 to 98%.
The behavioral survey did not include queries about the frequency
with which subjects had intercourse with each of their partners, so
the risk of acquisition of additional HIV strains from the partner
under study relative to other casual partners could not be
quantified.
Sequence and phylogenetic data
During the first phase of sequencing, we obtained 206
independent env sequences (C2-V5 region) from endpoint dilution
PCR reactions, which amplified individual viral templates,
(median 12.5 per subject, range 4–21). Three of the 8 couples’
HIV env sequences clustered in monophyletic groups, (couples D,
G, and H, Figure 1), suggesting that one partner may have
acquired HIV from the other, that they both acquired HIV from
the same individual or other closely-linked individuals, or that
following superinfection the second strain displaced the strain
acquired during primary infection. No monophyletic lineages were
detected in sequences from the remaining 5 couples (couples A, B,
E, F, and I), thus initially suggesting absence of transmission or
superinfection.
Subject A1 had sequences from the first and last study visits that
contained two distinct lineages indicating dual infection, but
neither strain clustered with those from his partner, subject A2
Table 3. Pooled behavioral data at study entry and during follow-up.
Baseline Behavioral Data Follow-up Behavioral Data
Partners
past yr
Partners
past
4m o
Insertive
without
condom
Receptive
without
condom
Total
Insertive
Total
Receptive
Partners
outside
primary
relationship
Insertive
without
condom
Receptive
without
condom
Total
Insertive
Total
Receptive
Total 109 27 119 105 147 143 167 905 629 1249 842
% - - 81% 73% - - - 72% 75% - -
Median/subject 1.5 1 3 4 6 5 10.5 49 27 80 29
Pooled behavioral data during follow-up.
doi:10.1371/journal.pone.0005690.t003
Table 2. Anogenital lesions during follow-up.
Couple Subject Anal warts Penile warts Anogenital HSV Episodes/couple
A1 4 - - 7
21 1 1
B3 - - 3 5
42 - -
D5 - - - 9
62 - 7
E7 - - 4 4
8- - -
F9 6 9 5 2 4
10 2 - 2
G1 1 - 2 - 2
12 - - -
H1 3 - - - 1
14 - 1 -
I1 5 1 - - 1
16 - - -
Number of visits with anogenital lesions due to human papillomavirus and herpes simplex virus reported during follow-up.
doi:10.1371/journal.pone.0005690.t002
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PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5690(Figure 2). Figure 3 shows the distances for subject A1’s sequences
superimposed upon the distribution of pairwise nucleotide
distances within and between patients in the remainder of the
cohort, revealing a bimodal distribution, with distances compara-
ble to distances within and between other subjects in the cohort.
Finally, additional analyses confirmed that subject A1’s viral
sequences fell on two different branches when a phylogenetic tree
was constructed using sequences from epidemiologically unlinked
HIV-1 subtype B-infected subjects from major cities in the United
States as described in Anderson et al. 2003 (data not shown) [40],
also supporting the presence of dual infection.
We undertook a second phase of sequencing for the 5 pairs
whose viruses were phylogenetically unlinked. We obtained
sequences from anorectal swabs in subjects A1 (N=15), A2
(N=35), B3 (N=15), B4 (N=25), and F10 (N=18) and from
PBMC at 2 additional time points in subject A1 (N=36) and 3
additional time points in subject F9 (N=4). Amplification of viral
DNA from cell pellets from anorectal swab specimens in couples E
and I was unsuccessful. This second phase of sequencing did not
reveal phylogenetic linkage between the partners in any of these
pairs, again suggesting that superinfection was not occurring.
Strain-specific PCR results
Strain-specific PCR was performed on the PBMC DNA
specimens from Pairs A, B, and F. Primers were able to detect
each subject’s specific variants at a sensitivity of 1–2 copies per
reaction and no non-specific amplification of partner’s DNA was
seen (data not shown). The amount of DNA tested ranged from
0.5 to 2.7 ug, estimated to contain 8–236 viral templates (the
product of the number of PBMC and the proviral copy number in
each specimen). In Pairs E and I, PCR reactions with specific
primers were unsuccessful due to insufficient specificity. The
strain-specific PCR did not show evidence of the enrolled partners’
viral variants in any of the subjects tested.
Recombination analysis
We analyzed sequences from pairs whose viruses were phyloge-
netically unlinked for evidence of subgenic linkage by assessment of
viral recombination between sequences of each partner in the pair.
Of the 5 pairs (A, B, E, F, and I), the algorithm RIP 3.0 identified
potential recombinant sequences between partners in pairs B and F
(Figure 4). Subject B4 had 2 PBMC-derived sequences from the first
study visit that had regions similar to the sequences of his partner B3.
In one sequence, there were 2 regions of similarity, 27 and 13
nucleotides in length, containing 15 and 7 shared informative sites
that were detected by the InSites algorithm.In the other,therewere 3
regions of similarity, 8, 42, and 3 nucleotides in length, containing 1,
32, and 3 shared informative sites. All of these regions met the cutoff
for statistical significance at the 90% level. Subject F9 had 1 PBMC-
and 1 anorectal-derived sequence similar to those of his partner F10,
1fromthefirststudyvisitandanother2yearspost-enrollment.Inone
of these, there were 3 regions, 132, 4, and 44 nucleotides in length,
containing 43, 2, and 5 shared informative sites, for which the closest
matching sequence was from his partner F10. In the other sequence,
there were also 3 regions of similarity, 142, 4, and 42 nucleotides in
Figure 1. Neighbor-joining phylogenetic tree showing PBMC-
derived C2-V5 HIV envelope gene sequences from all members
of the cohort with bootstrap values calculated from 1000
bootstrap replicates for each major branch. Couples are
designated by colored letters (A, B, and D–I) and correspond to the
couples in Table 1. Colored bars and ovals distinguish sequences from
partners in each couple.
doi:10.1371/journal.pone.0005690.g001
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PLoS ONE | www.plosone.org 5 May 2009 | Volume 4 | Issue 5 | e5690Figure 2. Neighbor-joining tree showing PBMC- and anorectal mucosa-derived sequences from subject 1 and PBMC-derived
sequences from subject 2. Subject 1’s sequences are clustered on two separate branches, signifying infection with two different HIV strains, both
of which are distinct from his partner’s isolates (subject 2).
doi:10.1371/journal.pone.0005690.g002
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PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5690length, containing 45, 0, and 3 shared informative sites. However,
none of the regions in either of F9’s sequences met the significance
threshold at the 90% confidence level.
Restricting the alignment to phylogenetically informative sites
using the InSites program, we were able to identify sites of genetic
similarity between the partners in Pairs B and F (Figure 5). Pair B
had 264 informative sites. There were 2 large gaps of 12 and 21
nucleotides present in a majority of B3’s sequences, shared with 8
sequences from B4. These included 7 PBMC-derived sequences, 5
from the first and 2 from the final study visit, and 1 anorectal-
derived sequence from the final study visit. In 15 other areas across
the alignment that were 1–2 nucleotides in length, some or all of
these 8 sequences from B4 resembled the majority of sequences
from B3. Pair F had 203 informative sites. The 17 areas where 6
sequences from F10 resembled the majority of sequences from F9
were found across the entire alignment and ranged from 1–3
nucleotides in length. The 6 sequences from F10 included 4
anorectal-derived sequences from 3 time points after the first study
visit and 1 PBMC-derived sequence from the final study visit. A
gap region ranging from 3–9 nucleotides in length was also present
in a majority of F10 and in 4 PBMC-derived sequences from F9, 1
from the first study visit and 3 from the final study visit.
In Pair A, for which RIP 3.0 did not identify recombinant
sequences, InSites analysis did show areas of similarity. Of 245
total informative sites, 34 areas 1–2 nucleotides in length were
present in a majority of one partner’s sequences and shared by a
subset of sequences in the other partner. In addition, there were 5
gaps 3–6 nucleotides in length present in nearly all of A2’s
sequences and a portion of A1’s sequences. These sites were found
across the alignment and involved both blood- and anorectal-
derived viruses from all time points evaluated. No compelling
evidence for genetic similarity suggestive of recombination was
found in Pairs E and I.
We also compared InSites output with sequences from pairs of
subjects in the cohort who were not expected to be epidemiolog-
ically linked to the results from the enrolled couples A, B, E, F, and
I. The mean proportion of informative sites that was shared by at
least 1 sequence from each individual was 30.4% (range 20.5–
45.7%) in the enrolled couples versus 25.3% (range 15.7–37.3%)
in 8 pairs without known epidemiologic linkage. However, there
was no statistically significant difference in the means (t-test, 2-
sided p=0.33). The number of shared sites that neighbored one
another did not appear to be different in the two groups, either.
Discussion
In this study, we sought to determine whether or not chronically
infected MSM on antiretroviral therapy can acquire HIV strains
Figure 3. Histogram showing the distribution of pairwise nucleotide distances within subject 1 versus those within and between
the remaining subjects in the cohort. Distances were calculated using an HKY85+I+C model estimated via maximum likelihood. The histogram
contains two peaks for subject 1, which overlie the peaks with distances for ‘among subjects’ and ‘within subjects’ for the cohort, demonstrating the
dual HIV infection in subject 1, with his two distinct sets of viral isolates.
doi:10.1371/journal.pone.0005690.g003
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may have occurred before the study period in 3 of the 8 enrolled
couples, as the subjects had viruses that clustered monophyletically
with those of their partners. In one of these 3 couples, both partners
reported that they were HIV-infected before their relationship
began. In this case, one subject may have superinfected the other,
but we were unable to detect the strain he had acquired during
primary infection. The other 5 couples had viruses that separated
into unlinked polyphyletic lineages for each partner, with pairwise
nucleotide distances consistent with independent sources of
infection. In addition, no related viruses were found with strain-
specific PCR in any of 3 evaluable pairs. Further investigation with
recombination detection algorithms showed that viruses from one
subjectmayhaverecombinedwiththosefromhis partnerin2 ofthe
5 couples whose viruses were unlinked in the phylogenetic tree, but
in only one of these cases was the threshold for statistical
significance met. In summary, after intensive evaluation, using
viral sequencing, phylogenetic analysis, strain-specific PCR, and
recombination detection algorithms in conjunction with epidemi-
ologic data, we found evidence suggestive of HIV superinfection in
2 of 8 HIV-1 seroconcordant MSM couples.
Although studies involving heterosexual couples, IDUs, and
individuals under ART in the United States failed to detect HIV-1
superinfection, despite large numbers of subjects and long follow-
up periods [41,42], recent data from other cohorts indicate that
dual and superinfection may be under-recognized. Three studies
have detected dual and superinfection at unexpectedly high rates
in ART-naı ¨ve individuals in Africa. Herbinger et al. reported the
prevalence of dual infection to be 9 and 19%, respectively, in
normal and high-risk cohorts in Tanzania [22] and Piantadosi et
al. found superinfection incidence rates of 3.7% and 7.7% per year
in two groups of female sex workers in Kenya [21,23]. Analyses of
viral recombination were used in all three of these studies.
Moreover, additional data providing indirect support of sexual
transmission of HIV-1 in seroconcordant MSM partners in the
United States has emerged. Willberg et al. have demonstrated that
Figure 4. RIP 3.0 analysis. Subject 4 in Pair B had 2 sequences for which 2–3 segments were more similar to one of his partner’s sequences than his
own with a significance threshold of 90%, shown by parallel green horizontal lines above the curves. The areas of similarity were at positions 400–426
and 450–462 for the first sequence and 331–338, 365–407, and 412–414 in the second sequence. Subject 9 in Pair F had 2 sequences for which 3
segments were similar to his partner Subject 10, shown by purple and aqua lines above the curves. These areas of similarity did not meet the
threshold for statistical significance of 90%. The areas of similarity were at positions 70–201, 204–207, and 519–552 in the first sequence and 70–211,
214–217, and 531–572 in the second sequence.
doi:10.1371/journal.pone.0005690.g004
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whose seroconcordant partners were viremic, had increased HIV-
specific T cell responses when compared to those whose partners
had undetectable plasma viral loads [43]. These data suggest that
occult superinfection in seroconcordant sexual partners may occur
more commonly than previously appreciated.
Our study had several unique components. We had access to
detailed sexual histories, confirming that risk behaviors were
occurring. Second, the ART and STI histories for all individuals
were available. Third, we utilized the additional laboratory
method of strain-specific PCR, which could detect low levels of
transmission with a higher level of sensitivity and specificity than
typical PCR methods. Finally, because we had partner pairs, we
were able to perform analysis for recombination between partners’
strains in those pairs whose viruses appeared unrelated by tree-
and distance-based phylogenetic methods and strain-specific PCR.
There are several potential causes for our inability to detect the
parental strain of the superinfecting virus in couples B and D. First,
we were unable to determine the precise timing of infection with
the partner’s virus, as this most likely occurred prior to enrollment
in the study. During each successive cycle of viral replication,
further recombination both obscures the ability to detect the
parental strains and blurs recombination breakpoints. Second, all
of these subjects received ART during at least some portion of the
follow-up period. Although three individuals (D5, H13, and I15)
had suppression of viral replication at all visits, none of these were
in couples with transmission detected during the study period. It is
reasonable to regard those who are taking antiretroviral
medications as at least partially protected from acquisition of
additional strains of HIV-1. Third, all viral sequences isolated
from the cohort were of subtype B, whereas many of the reported
dual and superinfection cases have occurred with viral strains of a
subtype different than that of the subject’s primary isolate [2–
8,21,22]. The substantially greater divergence between viruses in
inter-subtype transmissions facilitates the detection of superinfec-
tion and may account for their greater presence in the literature.
However, it is also possible that adaptive immunity provides better
protection against strains with a high degree of genetic similarity
[17,44]. Finally, all subjects in our study were in the chronic stage
of HIV-1 infection, when the CD4
+ T lymphocyte count almost
invariably has decreased significantly from baseline, leaving fewer
uninfected cells than in acute infection or after a period of
successful antiretroviral therapy (reviewed in [45] and [46]).
Therefore, in individuals with established HIV infection, fewer
host cells are vulnerable to incoming new viral strains, which may
reduce their risk for detectable superinfection.
Figure 5. Alignments of phylogenetically informative sites for Pairs A, B, and F, with shading indicating shared regions. Lavender:
nucleotide in upper partner’s sequences shared with lower partner’s sequences. Purple: nucleotide in lower partner’s sequences shared with upper
partner’s sequences. Yellow: gap.
doi:10.1371/journal.pone.0005690.g005
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algorithms were different. RIP, available for more than a decade
from the Los Alamos National Laboratory and widely used, works
by evaluating the similarity of a query sequence to an alignment
while moving stepwise across the alignment. The InSites algorithm
compares sequences in an alignment to a reference sequence and
shows each phylogenetically informative site, defined as a site at
which more than one sequence differs from the reference
sequence. The potential benefit to using InSites is to locate shared
sites in an alignment of sequences with limited diversity, where
recombination breakpoints may be closer together than the
minimum window size in a sliding window algorithm allows one
to detect. While RIP 3.0 found 2 sequences in one individual that
may have recombined with his partner’s virus at a 90% confidence
level, we were unable to detect a difference in the number of
shared informative sites that InSites revealed in the enrolled
couples versus the pairs with no known epidemiologic link. The
small sample size in our cohort may explain our inability to detect
a difference in shared informative sites between these 2 groups.
However, it also may be the case that the overall number of shared
sites is of lesser importance than their relative positions when
evaluating for recombination.
Three of the couples in our study (D, G, and H) had viral
sequences with a high degree of similarity (Figure 1). That initial
acquisition of the same HIV strain could have occurred for pairs G
and H can be inferred from their behavioral data in Table 1,
showing that their partnership pre-dated their perceived year of
HIV acquisition. However, the same conclusion cannot be drawn
for couple D, as each reported acquiring HIV in 1988, 4 years
before partnership formation. Given that separate phylogenetic
trees from each of these pairs did not support ongoing transmission
between partners during the study period, three explanations for
the similarity between their sequences exist. First, one partner in
the couple had transmitted HIV to the other before enrollment.
Second, both partners were infected by a third source partner or
other closely linked sources. Finally, HIV transmission from one
partner to the other had occurred prior to study entry, with
consequent overgrowth of the superinfecting strain, leading to
inability to detect the primary infecting strain. The latter has been
described in several case reports [4,26]. Our study cannot formally
distinguish among these possibilities.
In summary, in this cohort of 8 seroconcordant couples with
chronic HIV-1 infection receiving ART, we observed one couple
in which HIV superinfection may have occurred but was only
detectable by recombination analysis and another couple in which
one partner may have superinfected the other prior to study
enrollment, based on epidemiologic and phylogenetic evidence.
According to the objective clinical and self-reported behavioral
data, the subjects in our cohort were at increased risk for sexually
acquired superinfection. Their ART adherence was incomplete, as
evidenced by the proportion of visits with detectable viral loads, a
pattern not uncommon in ART-treated cohorts [47]. Although
our study was not designed to determine whether the acquisition of
additional viral strains led to clinical consequences, both dual and
superinfection have been associated with antiretroviral drug
resistance [24,25] and accelerated progression to AIDS [10,26].
The evidence for viral transmission in these couples should elicit
concern on the part of HIV-infected persons with seroconcordant
sexual partners. In particular, these data are a reminder that
precautionary measures among HIV-infected individuals are
necessary, as HIV-1 superinfection may occur even while under
ART. Thus, we advocate that public health messages advising
condom use [48–50] continue to be heeded, including by HIV-1
seroconcordant couples.
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